Context Therapeutics Statistics
Total Valuation
CNTX has a market cap or net worth of $25.27 million. The enterprise value is -$17.48 million.
| Market Cap | 25.27M |
| Enterprise Value | -17.48M |
Important Dates
The next estimated earnings date is Wednesday, November 4, 2026, after market close.
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CNTX has 91.88 million shares outstanding. The number of shares has increased by 7.82% in one year.
| Current Share Class | 91.88M |
| Shares Outstanding | 91.88M |
| Shares Change (YoY) | +7.82% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 1.36% |
| Owned by Institutions (%) | 42.67% |
| Float | 63.73M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.73 |
| P/TBV Ratio | 0.68 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.81, with a Debt / Equity ratio of 0.01.
| Current Ratio | 5.81 |
| Quick Ratio | 5.45 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -76.14% and return on invested capital (ROIC) is -50.28%.
| Return on Equity (ROE) | -76.14% |
| Return on Assets (ROA) | -45.70% |
| Return on Invested Capital (ROIC) | -50.28% |
| Return on Capital Employed (ROCE) | -127.39% |
| Weighted Average Cost of Capital (WACC) | 13.56% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$3.06M |
| Employee Count | 15 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -80.36% in the last 52 weeks. The beta is 1.72, so CNTX's price volatility has been higher than the market average.
| Beta (5Y) | 1.72 |
| 52-Week Price Change | -80.36% |
| 50-Day Moving Average | 0.40 |
| 200-Day Moving Average | 1.54 |
| Relative Strength Index (RSI) | 29.83 |
| Average Volume (20 Days) | 1,006,443 |
Short Selling Information
The latest short interest is 4.71 million, so 5.12% of the outstanding shares have been sold short.
| Short Interest | 4.71M |
| Short Previous Month | 6.91M |
| Short % of Shares Out | 5.12% |
| Short % of Float | 7.39% |
| Short Ratio (days to cover) | 3.89 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -48.73M |
| Pretax Income | -45.96M |
| Net Income | -45.96M |
| EBITDA | -48.71M |
| EBIT | -48.73M |
| Earnings Per Share (EPS) | -$0.48 |
Balance Sheet
The company has $42.99 million in cash and $244,992 in debt, with a net cash position of $42.75 million or $0.47 per share.
| Cash & Cash Equivalents | 42.99M |
| Total Debt | 244,992 |
| Net Cash | 42.75M |
| Net Cash Per Share | $0.47 |
| Equity (Book Value) | 38.17M |
| Book Value Per Share | 0.42 |
| Working Capital | 37.93M |
Cash Flow
In the last 12 months, operating cash flow was -$33.97 million and capital expenditures -$55,746, giving a free cash flow of -$34.03 million.
| Operating Cash Flow | -33.97M |
| Capital Expenditures | -55,746 |
| Depreciation & Amortization | 19,465 |
| Net Borrowing | n/a |
| Free Cash Flow | -34.03M |
| FCF Per Share | -$0.37 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CNTX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -7.82% |
| Shareholder Yield | -7.82% |
| Earnings Yield | -176.50% |
| FCF Yield | -130.68% |
Analyst Forecast
The average price target for CNTX is $4.03, which is 1,365.46% higher than the current price. The consensus rating is "Buy".
| Price Target | $4.03 |
| Price Target Difference | 1,365.46% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |